The aim of this study is to determine the efficacy of REG1 compared to bivalirudin in preventing periprocedural ischemic complications and major bleeding in patients undergoing PCI as a treatment for CAD.
- Patient Population – Patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI.)
- Sponsor – Regado Biosciences, Inc. ; The Cleveland Clinic ; Duke Clinical Research Institute; Canadian VIGOUR Centre; Icahn School of Medicine at Mount Sinai; Parexel
- Contact Information – (402) 384 – 2705, MPCHeartConsultantsResearch@nmhs.org
- Clinical Trials Government Link
This Study Is Closed To Enrollment.